EP4039247A3 - Formulation sublinguale de riluzole - Google Patents
Formulation sublinguale de riluzole Download PDFInfo
- Publication number
- EP4039247A3 EP4039247A3 EP21169884.0A EP21169884A EP4039247A3 EP 4039247 A3 EP4039247 A3 EP 4039247A3 EP 21169884 A EP21169884 A EP 21169884A EP 4039247 A3 EP4039247 A3 EP 4039247A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- riluzole
- sublingual formulation
- sublingual
- disclosed
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004181 riluzole Drugs 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 206010031009 Oral pain Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083094P | 2014-11-21 | 2014-11-21 | |
EP19186196.2A EP3616686B8 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
PCT/US2015/061114 WO2016081472A1 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
EP15823415.3A EP3220891B1 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15823415.3A Division EP3220891B1 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
EP19186196.2A Division-Into EP3616686B8 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
EP19186196.2A Division EP3616686B8 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4039247A2 EP4039247A2 (fr) | 2022-08-10 |
EP4039247A3 true EP4039247A3 (fr) | 2022-11-16 |
Family
ID=55085882
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19186196.2A Active EP3616686B8 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
EP21169884.0A Pending EP4039247A3 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
EP15823415.3A Active EP3220891B1 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19186196.2A Active EP3616686B8 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15823415.3A Active EP3220891B1 (fr) | 2014-11-21 | 2015-11-17 | Formulation sublinguale de riluzole |
Country Status (24)
Country | Link |
---|---|
US (2) | US11660267B2 (fr) |
EP (3) | EP3616686B8 (fr) |
JP (3) | JP6753860B2 (fr) |
KR (2) | KR20230135183A (fr) |
CN (1) | CN107249567B (fr) |
AU (2) | AU2015350148B2 (fr) |
BR (1) | BR112017010423B1 (fr) |
CA (1) | CA2967662A1 (fr) |
CY (1) | CY1122469T1 (fr) |
DK (1) | DK3220891T3 (fr) |
EA (1) | EA038518B1 (fr) |
ES (2) | ES2751300T3 (fr) |
HR (1) | HRP20191892T8 (fr) |
HU (1) | HUE046869T2 (fr) |
IL (2) | IL252285B (fr) |
LT (1) | LT3220891T (fr) |
MX (1) | MX368838B (fr) |
PH (1) | PH12017500934A1 (fr) |
PL (1) | PL3220891T3 (fr) |
PT (1) | PT3220891T (fr) |
RS (1) | RS59490B1 (fr) |
SG (1) | SG11201703896QA (fr) |
SI (1) | SI3220891T1 (fr) |
WO (1) | WO2016081472A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3038979A1 (fr) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Composes et procedes pour la degradation ciblee du recepteur des androgenes |
JP7354123B2 (ja) | 2018-02-21 | 2023-10-02 | エイアイ・セラピューティクス・インコーポレーテッド | アピリモドとグルタミン酸作動薬を用いた併用療法 |
EP3801626A4 (fr) * | 2018-05-27 | 2022-02-23 | Biohaven Pharmaceutical Holding Company Ltd. | Utilisation de comprimés orodispersibles à base de riluzole pour le traitement de maladies |
CA3109769A1 (fr) * | 2018-08-16 | 2020-02-20 | Biohaven Therapeutics Ltd. | Utilisation de comprimes orodispersibles a base de riluzole pour le traitement de maladies |
JP2022553954A (ja) * | 2019-10-22 | 2022-12-27 | アルビナス・オペレーションズ・インコーポレイテッド | 前立腺癌を治療する方法 |
KR20230015933A (ko) | 2020-05-09 | 2023-01-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 이작용성 화합물, 이작용성 화합물의 초순수 형태, 및 이를 포함하는 투여 형태를 제조하는 방법 |
US20240016783A1 (en) * | 2020-10-05 | 2024-01-18 | Icahn School Of Medicine At Mount Sinai | Riluzole for the treatment of alzheimer's disease |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
CN113876735B (zh) * | 2021-10-20 | 2023-05-12 | 陇南市第一人民医院 | 一种利鲁唑微球制剂及其制备方法 |
KR102625977B1 (ko) | 2021-11-24 | 2024-01-17 | 부산대학교 산학협력단 | 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096869A1 (fr) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | Agent permettant d'améliorer l'inotropie et la lusitropie et de traiter des maladies provoquant ou provoquées par une contractilité ou un relâchement médiocre du cœur |
WO2010102923A2 (fr) * | 2009-03-13 | 2010-09-16 | Italfarmaco Spa | Suspensions aqueuses de riluzole |
WO2016140878A2 (fr) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Promédicaments de riluzole et leur procédé d'utilisation |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
FR2702148B1 (fr) * | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
CA2166891C (fr) | 1993-07-09 | 2001-07-03 | Sang K. Wong | Methode pour l'obtention de formes posologiques par lyophylisation |
US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
DE59711346D1 (de) * | 1996-12-20 | 2004-04-01 | Nutrinova Gmbh | Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe |
ES2318869T3 (es) | 1997-02-20 | 2009-05-01 | Massachusetts Institute Of Technology | Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. |
EP1001748B1 (fr) | 1997-07-25 | 2006-04-19 | Alpex Pharma S.A. | Procede de preparation de granules servant a produire des comprimes solubles dans la bouche a desintegration rapide |
AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
EP1135105B1 (fr) * | 1998-12-09 | 2005-03-02 | Chiron Corporation | Utilisation d'un agent neurologique pour la preparation d'un medicament pour le traitement d'une maladie du systeme nerveux central |
FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
JP2001328947A (ja) * | 2000-05-19 | 2001-11-27 | Ritsuko Senba | 脳由来神経栄養因子発現促進剤 |
US6432992B1 (en) * | 2000-06-05 | 2002-08-13 | Aventis Pharm Sa | Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
CA2476250C (fr) | 2002-02-13 | 2010-08-03 | Michael K. Weibel | Forme posologique medicamenteuse et procede de fabrication |
EP2316468A1 (fr) * | 2002-02-22 | 2011-05-04 | Shire LLC | Système de distribution et méthodes de protection et d'administration de dextroamphetamine |
WO2004105756A2 (fr) * | 2003-05-29 | 2004-12-09 | Novartis Ag | Combinaison contenant un agent neuroprotecteur et un agent se fixant a la gadph, et utilisation pharmaceutique associee |
US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
CA2558380A1 (fr) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Therapie de combinaison avec acetate de glatiramer et riluzole |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
EP1980240A1 (fr) | 2007-04-11 | 2008-10-15 | Cephalon France | Composition pharmaceutique lyophilisée et leurs procédés de fabrication et d'utilisation |
WO2009002084A2 (fr) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Procédé de préparation d'une formulation à désagrégation rapide pour l'administration par voie orale et appareil de préparation et de conditionnement correspondant |
US20110183942A1 (en) * | 2008-07-15 | 2011-07-28 | University Of Medicine And Dentistry Of New Jersey | Methods and Compositions for Treating Alzheimer's Disease |
US8256233B2 (en) | 2008-10-31 | 2012-09-04 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
US8545806B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
DK2560631T3 (da) * | 2011-03-01 | 2014-02-10 | Pharnext | Baclofen- og acamprosat-baseret af neurologiske forstyrrelser |
WO2013010015A2 (fr) * | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Polythérapie pour als |
IN2014DN07989A (fr) | 2012-03-01 | 2015-05-01 | Pharnext | |
CN107735077A (zh) | 2014-11-21 | 2018-02-23 | 拜尔哈文制药股份有限公司 | 利鲁唑的舌下给药 |
-
2015
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 KR KR1020237031525A patent/KR20230135183A/ko not_active Application Discontinuation
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active IP Right Grant
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/fr active Active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/fr active Application Filing
- 2015-11-17 EP EP21169884.0A patent/EP4039247A3/fr active Pending
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/fr active Active
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 CA CA2967662A patent/CA2967662A1/fr active Pending
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
-
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
- 2017-05-19 PH PH12017500934A patent/PH12017500934A1/en unknown
-
2019
- 2019-10-18 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
-
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-20 IL IL278188A patent/IL278188A/en unknown
- 2020-10-25 US US17/079,498 patent/US20210038499A1/en active Pending
-
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
-
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010096869A1 (fr) * | 2009-02-26 | 2010-09-02 | Steven Michael Weiss | Agent permettant d'améliorer l'inotropie et la lusitropie et de traiter des maladies provoquant ou provoquées par une contractilité ou un relâchement médiocre du cœur |
WO2010102923A2 (fr) * | 2009-03-13 | 2010-09-16 | Italfarmaco Spa | Suspensions aqueuses de riluzole |
WO2016140878A2 (fr) * | 2015-03-03 | 2016-09-09 | Biohaven Pharmaceutical Holding Company Ltd. | Promédicaments de riluzole et leur procédé d'utilisation |
Non-Patent Citations (3)
Title |
---|
ANONYMOUS: "Riluzole in Mild Alzheimer's Disease Study: NCT01703117", 21 November 2013 (2013-11-21), XP055965242, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01703117?V_3=View#StudyPageTop> [retrieved on 20220927] * |
REED M N: "The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease", 44TH ANNU MEET SOC NEUROSCI, 16 November 2014 (2014-11-16), XP055965232, Retrieved from the Internet <URL:https://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e5ed7920-d623-41df-be15-f16360644d04&cKey=5d515aae-d80c-46fb-a950-909ddcb7d904&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7> * |
WEITZNER D.: "Riluzole attenuates spatial memory deficits in a TauP301L mouse model of Alzheimer's disease", 44TH ANNU MEET SOC NEUROSCI, 15 November 2014 (2014-11-15), XP055965230, Retrieved from the Internet <URL:https://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3527&sKey=a7fe65d1-e9f1-4a0d-976f-a57be5b3955a&cKey=f51e058a-67b5-4c8a-9c86-4ca6b563a000&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7#> * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4039247A3 (fr) | Formulation sublinguale de riluzole | |
PH12017500933A1 (en) | Sublingual administration of riluzole | |
MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
MX2017004471A (es) | Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística. | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
EP4289822A3 (fr) | Benzoimidazol-1,2-yl amides en tant qu'activateurs du canal kv7 | |
NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
PH12016502530A1 (en) | Pharmaceutical compositions comprising dgla and use of same | |
PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
PH12016501483B1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
WO2016080796A3 (fr) | Composition pharmaceutique contenant un composé sesquiterpénique et utilisable en vue de la prévention ou du traitement de maladies à médiation par stat3, et son utilisation | |
TW201613639A (en) | Methods for treating cardiovascular diseases | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
IL248428B (en) | 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
WO2016082807A3 (fr) | Nouvelle utilisation d'itraconazole | |
MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
EP4335508A3 (fr) | (+)-azasetron destiné à être utilisé dans le traitement de troubles de l'oreille | |
WO2016073652A8 (fr) | Iminosucres utiles pour le traitement de maladies virales | |
MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. | |
UA104614U (uk) | Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих | |
ITUB20153076A1 (it) | Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento. | |
UA108139U (uk) | Спосіб терапії корів з ендометритом, як профілактика гонадопатій |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3220891 Country of ref document: EP Kind code of ref document: P Ref document number: 3616686 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/30 20060101ALI20221007BHEP Ipc: A61P 25/28 20060101ALI20221007BHEP Ipc: A61P 25/24 20060101ALI20221007BHEP Ipc: A61P 25/22 20060101ALI20221007BHEP Ipc: A61P 25/18 20060101ALI20221007BHEP Ipc: A61P 25/16 20060101ALI20221007BHEP Ipc: A61P 25/00 20060101ALI20221007BHEP Ipc: A61K 47/26 20060101ALI20221007BHEP Ipc: A61K 47/20 20060101ALI20221007BHEP Ipc: A61K 31/428 20060101ALI20221007BHEP Ipc: A61K 9/20 20060101ALI20221007BHEP Ipc: A61K 9/08 20060101ALI20221007BHEP Ipc: A61K 9/00 20060101AFI20221007BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40077183 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230516 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231025 |